Home > Journals > Gastroenterology International

Gastroenterology International

Submit your article Read this Journals View all journals
Full Text (PDF)
Case Report

A Case of Persistent Transaminitis and Quadriparesis Due to Entecavir in Hepatitis B Patient with Underlying Chronic Kidney Disease

Viswanath Reddy Donapati, Suresh Babu V.

Author Information

Licence:

Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.

Gastroenterology International 8(2):p 56-58, july-dcec 2023. | DOI: 10.21088/gi.2456-5458.8223.3

How Cite This Article:

Donapati VR, V Suresh B. A Case of Persistent Transaminitis and Quadriparesis Due to Entecavir in Hepatitis B Patient with Underlying Chronic Kidney Disease. Gastro Int. 2023;8(2):55–7.

Timeline

Received : September 16, 2023         Accepted : October 30, 2023          Published : November 21, 2023

Abstract

Introduction: Oral antivirals for Hepatitis B treatment are relatively safe but rarely  complications are described. We hereby describe a case of chronic kidney disease (CKD)  with Hepatitis B infection who presented with muscle weakness due to rhabdomyolysis after  starting on Entecavir which recovered on stopping it. Case report: A 52 year old male, a patient of Diabetic Nephropathy, was initiated on dialysis  elsewhere and within few weeks developed jaundice and was screened positive for Hepatitis  B with high viral load. Entecavir was initiated, 5 days later he presented to us with leg pains  and quadriparesis. On evaluation, he had deranged liver function test (LFT),elevated LDH and  CPK levels. We stopped Entecavir as we noted reports of rhabdomyolysis with Entecavir with statin  combination. He was hydrated appropriately. Haemodialysis was continued. The patient showed gradual improvement in LFT and quadriparesis. The learning point  from this case was identifying the complication and taking action for good outcome. Conclusion: This is the first case of drug (Entecavir) induced Rhabdomyolysis in a patient  with CKD, Acute Hepatitis B, presenting with quadriparesis. Entecavir may be avoided in  CKD patients in whom Tenofovir Alafenamide may be safer.

References

  • 1.   Wang W, Lu X, Li C, Teng W, Cùi W. Rhabdomyolysis induced by Rosuvastatin combined with Entecavir: A case report. BMC Infect Dis. 2022;22:365.
  • 2.   Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore). 2005 Nov;84(6):377–85.
  • 3.   Stanley M, Chippa V, Aeddula NR, Quintanilla Rodriguez BS, Adigun R. Rhabdomyolysis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 28846335.
  • 4.   Wu K, Xu X, Huang L, et al. Telbivudine induced Rhabdomyolysis in a patient undergoing haemodialysis: A case report and review of literature. J Int Med Res. 2023 Dec;51(12):03000605231222244.
  • 5.   Hohenegger M. Drug induced rhabdomyolysis. Curr Opin Pharmacol. 2012 Jun;12(3):335–9. doi: 10.1016/j.coph.2012.04.002.

Data Sharing Statement

There are no additional data available.

Funding

This research received no funding.

Author Contributions

All authors contributed significantly to the work and approve its publication.

Ethics Declaration

This article does not involve any human or animal subjects, and therefore does not require ethics approval.

Acknowledgements

Information Not provided.

Conflicts of Interest

The authors report no conflicts of interest in this work.

About this article

Cite this article

Donapati VR, V Suresh B. A Case of Persistent Transaminitis and Quadriparesis Due to Entecavir in Hepatitis B Patient with Underlying Chronic Kidney Disease. Gastro Int. 2023;8(2):55–7.

Licence:

Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.

Received Accepted Published
September 16, 2023 October 30, 2023 November 21, 2023
DOI: 10.21088/gi.2456-5458.8223.3

Keywords

Entecavirtest 01test 02test 03

Article Level Metrics

Last Updated

Saturday 27 June 2026, 15:09:33 (IST)

1014

Accesses

15
52
00

Citations


NA
NA
NA

Download citation


Article Keywords

Keyword Highlighting

Highlight selected keywords in the article text.


Timeline

Received September 16, 2023
Accepted October 30, 2023
Published November 21, 2023

licence

Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.


Access this article

Reprint Order Form
Buy this Article
Institutional Subscriptions

Share